title: PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.
abstract: Irisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (PPAR-α). We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hypertriglyceridemia. This study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia (group A) and 40 controls (group B). Group A was treated with fenofibrate (200 mg/day) for 8 weeks. Serum irisin and clinical characteristics were examined. Serum irisin was significantly higher in group A compared with group B (45.15 ± 10.48 versus 35.38 ± 9.97 ng/ml, P < 0.001) and correlated with body mass index (r = 0.314, P = 0.011), fasting blood glucose (r = 0.399, P = 0.001), total cholesterol (r = 0.256, P = 0.040), and high-density lipoprotein cholesterol (r = 0.247, P = 0.047). In multiple regression analysis after controlling for confounders, only fasting blood glucose (β = 5.615, P < 0.001) and high-density lipoprotein cholesterol (β = 19.483, P < 0.001) were independently related to serum irisin. After 8 weeks of fenofibrate treatment, serum irisin significantly decreased in group A compared with baseline (45.15 ± 10.48 versus 38.74 ± 12.54 ng/ml, P = 0.011). Conclusively, fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia, indicating that PPAR-α agonists may protect against metabolic disorders by improving irisin resistance.
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Xiaomeng
authors.initials: X
authors.lastname: Feng
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Heng
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Qingrong
authors.initials: Q
authors.lastname: Pan
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yao
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Yang
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Guang
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Xinchun
authors.initials: X
authors.lastname: Yang